awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38931842-39982AA6-BAC8-4773-BAFD-DAA031EB590D
Q38931842-39982AA6-BAC8-4773-BAFD-DAA031EB590D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38931842-39982AA6-BAC8-4773-BAFD-DAA031EB590D
SGLT2 Inhibitors: Benefit/Risk Balance.
P2860
Q38931842-39982AA6-BAC8-4773-BAFD-DAA031EB590D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38931842-39982AA6-BAC8-4773-BAFD-DAA031EB590D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
c2e241a4b562041e8f302908296d504f2af94299
P2860
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.